ApconiX Welcomes Dr Bjorn Dahl ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development [...]
Professor Ruth Roberts on SOT Ballot ApconiX is happy to announce that Professor Ruth Roberts is on the SOT ballot for the position of Vice President-Elect. As Secretary to SOT, Ruth was the first non-US based Council member and now hopes to be the first non-US based President! ‘It’s [...]
Highlight Article for Experimental Biology and Medicine “Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration”, co-authored by Abigail L Walker, Syed Z Imam and Ruth A Roberts, has been selected as a highlight article for Experimental Biology and Medicine’s 243:13 issue. As a result of this designation it [...]
Choosing the right non-clinical CRO Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical [...]
Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst [...]
Two of the biggest ethical challenges in pharmaceutical toxicology are the use of animals in testing and the high safety-related attrition rates in new drug development. Yet very little is invested in these two fields compared with investment in new efficacy models, new disease targets and new technologies. How can this be addressed? In this [...]
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]
In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]
